Net loss (In thousands)

Depreciation and amortization (In thousands)

Provision for credit losses (In thousands)

Provision for inventory obsolescence (In thousands)

Share-based compensation (In thousands)

Loss/(gain) from disposal of property and equipment (In thousands)

Unrealized foreign currency (gain)/loss, net (In thousands)

Amortization of right-to-use asset (In thousands)

Stock compensation in lieu of cash fees (In thousands)

Interest capitalized for construction in progress (In thousands)

Non-cash interest expense and amortization of debt discount (In thousands)

Accounts receivable (change) (In thousands)

Inventory (change) (In thousands)

Prepaid expenses and other current assets (change) (In thousands)

Other assets (change) (In thousands)

Accounts payable (change) (In thousands)

Accrued liabilities (change) (In thousands)

Operating lease liabilities (change) (In thousands)

Other liabilities (change) (In thousands)

Net cash used in operating activities (In thousands)

Purchases of property and equipment (In thousands)

Cash used in business acquisitions, net of cash acquired (In thousands)

Cost incurred for intangible assets (In thousands)

Capital expenditures on construction in progress (In thousands)

Net cash used in investing activities (In thousands)

Issuance of common stock, net of underwriters’ discount and issuance costs (In thousands)

Proceeds from stock option exercises (In thousands)

Tax payments related to shares withheld upon vesting of restricted stock (In thousands)

Net cash provided by financing activities (In thousands)

Effect of exchange rate changes on cash and cash equivalents (In thousands)

Net (decrease)/increase in cash and cash equivalents (In thousands)

Cash paid for interest (In thousands)

Cash paid for income taxes (In thousands)

Cash at beginning of period (In thousands)

Cash and cash equivalents at end of period (In thousands)

53a0cae46842b9f101d1244b4d120e58313f56f9cb862ec53875d356657b5f9c

Revenue (USD, thousands)

Cost of revenue (USD, thousands)

Gross profit (USD, thousands)

Sales, general and administrative expenses (USD, thousands)

Research and development expenses (USD, thousands)

Total operating expenses (USD, thousands)

Loss from operations (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Other income (expense), net (USD, thousands)

Loss before income taxes (USD, thousands)

Benefit (provision) for income taxes (USD, thousands)

Net loss (USD, thousands)

Basic and diluted net loss per share (USD)

Weighted average outstanding shares used for basic and diluted net loss per share (Shares)

4f532a467bf0dfb1d479214ae53d418a865d0d458b276f195097539b0104897f

Number of countries where Motiva Implants are commercially available (countries)

Total Motiva Implants sold (implants)

Total product complaints for Motiva Implants (complaints)

Cases of early seroma for Motiva Implants (cases)

Cases of late seroma for Motiva Implants (cases)

Reported rupture rate for Motiva Implants (percentage)

Reported capsular contracture rate for Motiva Implants (percentage)

Reported reoperation rate for adverse events for Motiva Implants (percentage)

Number of consecutive cases in the Dolan Park independent study (cases)

Overall complication and reoperation rate in the Dolan Park independent study (percentage)

Number of patients in the Mia Femtech IRB study (patients)

Follow-up compliance rate in the Mia Femtech IRB study (percentage)

Capsular contracture rate in the Mia Femtech IRB study (percentage)

Rupture rate in the Mia Femtech IRB study (percentage)

Reoperation rate in the Mia Femtech IRB study (percentage)

Number of patients in the Motiva US IDE study - primary augmentation cohort (patients)

Number of patients in the Motiva US IDE study - revision augmentation cohort (patients)

Follow-up compliance rate in the Motiva US IDE study - primary augmentation cohort (percentage)

Capsular contracture rate in the Motiva US IDE study - primary augmentation cohort (percentage)

Rupture rate in the Motiva US IDE study - primary augmentation cohort (percentage)

Reoperation rate in the Motiva US IDE study - primary augmentation cohort (percentage)

Any complication rate in the Motiva US IDE study - primary augmentation cohort (percentage)

Projected additional annual manufacturing capacity from new CFZ facility (units per year)

a1a8585561f769e4981430cf301671358d620cd2448adae954e2df5ad88f4ecd

Cash and cash equivalents (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory, net (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net of accumulated depreciation (USD, thousands)

Goodwill (USD, thousands)

Intangible assets, net of accumulated amortization (USD, thousands)

Right-of-use operating lease assets, net (USD, thousands)

Other non-current assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Other liabilities, short-term (USD, thousands)

Total current liabilities (USD, thousands)

Note payable, net of debt discount and issuance costs (USD, thousands)

Operating lease liabilities, non-current (USD, thousands)

Other liabilities, long-term (USD, thousands)

Total liabilities (USD, thousands)

Total shareholders’ equity (USD, thousands)

Total liabilities and shareholders’ equity (USD, thousands)

d7812e5e0727ff14f75e2a743a7582d74fccc000bd2c6fc254bfd06df6331dfa

Motiva Breast Implants

Motiva Sales in the US

Total Revenue

5b1498cafac31f78a4c1bbfd6142daa97993b9828e50c145083366f110c6c1b7

Establishment Labs Holdings Inc (ESTA)

Financials